Valuation: Relay Therapeutics, Inc.

Market Cap 4.1B 3.57B 3.32B 3.05B 5.76B 392B 5.85B 39.14B 15.36B 195B 15.41B 15.07B 654B P/E 2026 *
-12.2x
P/E 2027 * -11.9x
Enterprise Value 3.81B 3.31B 3.08B 2.83B 5.35B 364B 5.43B 36.36B 14.27B 181B 14.32B 14B 607B EV / Sales 2026 *
323x
EV / Sales 2027 * 268x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day-3.19%
1 week+2.11%
1 month+6.02%
3 months+48.03%
6 months+145.82%
Current year+122.58%
1 week 17.71
Extreme 17.71
19.8
1 month 17.71
Extreme 17.71
20.79
Current year 7.01
Extreme 7.01
20.79
1 year 3.02
Extreme 3.025
20.79
3 years 1.78
Extreme 1.775
20.79
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap.
7/28/26 A Sell

Chief Financial Officer

-1,459 0.0007%
7/28/26 A Sell

Executive/Senior Manager

-748 0.0003%
7/28/26 A Sell

Chief Technology Officer

-2,237 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-3.19%+2.11%+460.42%+58.10% 4.1B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.67%+1.16%+106.41%+85.69% 25.45B
Weighted average by Cap. -1.62%+2.04%+86.33%+107.74%

Financials

2026 *2027 *
Net sales 11.8M 10.26M 9.55M 8.77M 16.56M 1.13B 16.82M 113M 44.19M 561M 44.33M 43.36M 1.88B 14.5M 12.61M 11.73M 10.77M 20.34M 1.38B 20.66M 138M 54.28M 689M 54.46M 53.26M 2.31B
Net income -292M -254M -236M -217M -410M -27.9B -416M -2.79B -1.09B -13.89B -1.1B -1.07B -46.57B -312M -271M -253M -232M -438M -29.79B -445M -2.98B -1.17B -14.83B -1.17B -1.15B -49.73B
Net Debt -292M -254M -236M -217M -410M -27.88B -416M -2.79B -1.09B -13.88B -1.1B -1.07B -46.54B -221M -192M -179M -164M -310M -21.08B -315M -2.11B -827M -10.5B -829M -811M -35.2B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
31/07/26 $18.83 -3.19% 1,785,640
30/07/26 $19.45 +5.88% 1,866,020
29/07/26 $18.37 +0.44% 1,944,144
28/07/26 $18.29 -1.88% 2,933,295
27/07/26 $18.64 +1.08% 4,202,088
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.83USD
Average target price
26.08USD
Spread / Average Target
+38.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock